ArticleMedical science monitor : international medical journal of experimental and clinical research2020
Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC).
Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Expression of CXCL10 and CXCL16 in Triple-Negative Breast Cancer and Their Association with Immunotherapy Efficacy and Prognosis.International journal of women's health · 2026Article
- Subtype-specific genetic drivers of immune evasion in breast cancer.Immuno-oncology technology · 2025Article
- Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer.Cells · 2025Review
- A Small-Molecule Compound Targeting Canine Mammary Cancer Regulates CXCL10 and MECOM Transcripts via Histone Modifications in CMT-N7.Animals : an open access journal from MDPI · 2025Article
- Network-Based Integrative Analysis to Identify Key Genes and Corresponding Reporter Biomolecules for Triple-Negative Breast Cancer.Cancer medicine · 2025Article
- The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025Review
- Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.Bioinformatics and biology insights · 2025Article
- Genetic polymorphisms in cGAS-STING-mediated type I interferon innate immune signaling pathway are associated with DLBCL.Frontiers in immunology · 2025Article
- Global transcriptomic analysis of breast cancer and normal mammary epithelial cells infected with Borrelia burgdorferi.European journal of microbiology & immunology · 2023Article
- Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.Cancer management and research · 2023Article
- Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.Human genomics · 2022Article
- Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.Metabolites · 2022Review
- Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.Breast cancer research : BCR · 2022Article
- Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.Gynecologic oncology · 2022Article
- Drivers and suppressors of triple-negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.BMC cancer · 2021Article
- Article
- Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Efficacious therapy for triple negative breast cancer (TNBC) continues to be a profound clinical challenge, but the key driven genes and convoluted signaling pathways are still unknown. MATERIAL AND METHODS A total of 223 samples (163 TNBC and 60 healthy breast tissues) were taken and deeply integrated analyzed by R software from 4 expression profiles in the study, including GSE53752, GSE45827, GSE65194, and GSE38959. We examined differentially expressed genes (DEGs) and screen for critical genes and pathways enrichment. The protein‑protein interaction (PPI) network of DEGs-associated was built through the STRING Version: 11.0 database and Cytoscape software to filter the hub gene. Then, we verified hug gene expression levels through the Oncomine database. Also, we analyzed the prognostic value of TNBC patient's hub genes using the Kaplan-Meier plotter database. RESULTS In our study, we filter out 365 DEGs, including 212 upregulated genes and 153 downregulated genes. Then, 10 hub genes were picked out by the intersection of 12 algorithms. At the same time, we discovered that CXCR4 and CXCL10 overexpression are favorable prognostic factors for recurrence-free survival of TNBC through the Kaplan-Meier plotter database. CONCLUSIONS Our research found that CXCR4 and CXCL10 overexpressed, and they were a favorable prognostic factor in patients with TNBC. CXCR4 and CXCL10 might be effective targets for TNBC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.